MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies across the commercialization finish line. Earlier this year, MeiraGTx bought back botaretigene sparoparvovec (bota-vec) from Johnson & Johnson, despite the therapy failing to improve vision-guided mobility in patients with X-linked retinitis pigmentosa (XLRP) in a phase 3 trial . Despite the trial miss, the company touted “clinically meaningful benefit” seen in the data and s

Existing data supports direct path to resubmission following constructive FDA engagement July 7, 2026 -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for SL1009, sodium dichloroacetate (DCA), for the treatment of pyruvate dehydrogenase complex deficiency (PDCD), a rare, life-threatening mitochondrial disease with no FDA-approved therapies. The resubmi

Vertex Pharmaceuticals is making the largest acquisition bet in its history, announcing late Monday an agreement to purchase a biotechnology company, Crinetics Pharmaceuticals, that recently brought to market a new kind of medicine for a rare hormonal disorder. Vertex is paying $85 per share in cash, or $10 billion overall, for Crinetics. The deal ranks as the fourth largest, by total proceeds, in an already busy year for biotech company acquisitions, according to BioPharma Dive data. Additiona

July 7, 2026 -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced the completion of enrollment for the REPLACE™ Phase 1b/2a clinical trial of RNDP-001, an investigational cell therapy being developed for the treatment of moderate to moderate-severe idiopathic Parkinson's disease (iPD). RNDP-001 is an off the shelf, allogeneic neuron replacement cell therapy designed to restore dopaminergic neurons lo

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7th, at 8:30am ET July 07, 2026 -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinic

Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial and financial milestones July 07, 2026 --- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that it has entered into a securities purchas

Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and positive Phase IIa clinical results in Nature Medicine Rentosertib represents a novel mechanism, novel AI-identified target, and novel AI-empowered molecule emerging from Insilico's aging-biology-driven Pharma.AI platform The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, wit

July 7, 2026 -- Helix, the leading enterprise genomics company, today announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. GenoSphere cohorts consist of comprehensive Exome+® genomic and rich longitudinal clinical data, designed to accelerate Life Sciences research across the development cycle. The

July 7, 2026 -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million oversubscribed seed financing round led by Empirical Ventures, with participation from DEBRA Research, Cure EB, Oshen Bio and existing investor SFC Capital. Proceeds will support pre-clinical development, manufacturing scale-up, regulatory engagement with the MHRA and FDA, and progression toward first-in-h

Completion of enrollment anticipated within 12 months GALILEO-3 is intended to support the registration of FLT201 in the adult GD1 population July 07, 2026 -- Spur Therapeutics today announced that the first patient has been dosed in GALILEO-3, its Phase 3 pivotal clinical trial evaluating avigbagene parvec (FLT201), an investigational gene therapy for Gaucher disease type 1 (GD1). The trial will assess the safety and efficacy of FLT201 in adults currently on stable standard-of-care therapies.